ALK and neoplasm: MYCN amplification, activating mutations in the ALK receptor tyrosine kinase, TERT rearrangements, inactivating ATRX mutations and dominant negative mutations in PHOX2B are among the most recurrent genetic events that drive oncogenic signaling and tumor formation23,25,27,51–54.